News

Highest GDPR fine of 1.2 billion euros imposed by the Irish data protection authority in May 2023 for a breach of the rules on international data transfers. Further fines imposed by this authority in 2023 amounted to hundreds of millions of euros. The main violations are “Insufficient legal basis for data processing” and “Failure to comply with the general principles of data processing”. The next most common violation is “Insufficient technical and organizational measures to ensure information security”. Spain tops the list of countries with the most fines for the fifth year in a row, followed by Italy and Romania. Ireland, Luxembourg and France have the highest average fines and total amounts per country. Berlin – Today, international law firm CMS has published the fifth edition of its annual Enforcement Tracker Report. The English-language report shows the developments of all publicly known GDPR fines based on CMS's own online database, GDPR Enforcement Tracker. The current edition of the report covers the analysis period between March 2023 and March 2024. 510 fines were added for the past year as of the editorial deadline on 1 March 2024. This brings the total number of data protection fines since the GDPR came into effect in May 2018 to 2,225, or 2,086 if only fines with full details such as the amount of the fine, date and authority are counted. The total amount of fines since the start of the survey is around 4.5 billion euros. This means that fines of around 1.7 billion euros have been added compared to last year’s Enforcement Tracker Report. This shows that authorities are no longer shying away from imposing high fines. The average fine for the entire reporting period was around 2.1 million euros - with high fines against “big tech” companies in 2021/22 and the first fine in the billions in 2023 having a particularly heavy impact.“At the top of the list of GDPR fine triggers is, once again, insufficient legal basis and non-compliance with the general data processing principles as well as insufficient technical and organisational measures. Companies should pay particular attention to this,” says Christian Runte, lawyer and partner at the international commercial law firm CMS Germany. Dr Alexander Schmid from the Enforcement Tracker team at CMS Germany adds: “In addition to data protection authorities, the courts have also increasingly dealt with the interpretation of the GDPR. For example, the Court of Justice of the European Union has further clarified the scope of data subjects' right of access. “These rulings create more clarity, but at the same time tighten the requirements for companies, which is why, in addition to a viable compliance concept, current developments will also be decisive for them in practice in the future.”Read the full Enforcement Tracker Report here; a summary can be found here. Pressekon­takt presse@cms-hs. com

An article by Dr. Dirk Spacek and Julia Nitschke for WEKA

Zurich, May 2024 | ISS Facility Services AG acquires gammaRenax AG. gammaRenax is an accomplished quality provider of integral facility services with 1,800 employees at 16 offices spread across all regions of Switzerland. Versatility, flexibility and customer focus are key characteristics of the owner-managed company's understanding of service. With a portfolio of over 1,600 properties, gammaRenax is one of the most important facility services providers in Switzerland. With this acquisition, ISS seeks to strengthen its position as leading provider of comprehensive facility management services in Switzerland. There are synergies in the customer base and new competencies in the areas of hotel services and hygiene management for pools and wellness areas. With the FM Academy, gammaRenax also has profound expertise in training and further education in areas such as hygiene management, property maintenance and building services. These specialisations will complement the services offered by ISS Switzerland and provide the customers of both companies with an extended range of high-quality services. The seller, Severin Gallo, will join the board of ISS Facility Services AG. ISS Switzerland is the leading provider for workplace experience and facility management. ISS offers intelligent and scalable solutions that contribute to better business performance and make life easier, more productive and more enjoyable - developed to high standards and implemented responsibly by dedicated people. ISS employs around 12,500 people in Switzerland and 350,000 worldwide in over 30 countries.A team of CMS led by Dr Daniel Jenny has advised ISS on all legal aspects of this transaction. The further consisted of Dr Ferdinand Blezinger, Florian Jung, Christian Gersbach, Miryam Meile, Dr Dirk Spacek, Julia Nitschke and Helena Loretan. CMS Switzer­land­Daniel Jenny, Partner, Corporate / M&ADr Ferdinand Blezinger, Senior Associate, Corporate / M&A         Florian Jung, Senior Associate, Corporate / M&A    Christian Gersbach, Partner, Employment Dr Miryam Meile, Senior Associate, EmploymentDr Dirk Spacek, Partner, IP/ITJulia Nitschke , Associate, IP/ITHelena Loretan, Associate, Real estate  

We are pleased to welcome a new Counsel to our team as from 1 May 2024.

An article by Dr. Vaïk Müller for Agefi

An article by Audrey Durand for GesKR

Zurich, March 2024 | Vista Klinik Holding AG, domiciled in Binningen (Switzerland), integrated into its network Augenzentrum Muttenz-Pratteln GmbH, a renowned provider of ophthalmological services in Baselland. The eye centre operates a total of three ultra-modern sites in the municipalities of Muttenz and Pratteln with first-class medical equipment, including state-of-the-art surgery facilities (focused on intravitreal injections). Founded over 30 years ago, Vista Augenpraxen & Kliniken has become a leading centre of excellence for ophthalmology in Switzerland. With its numerous locations, Vista has a broad network of eye clinics and eye practices. At all sites, specialised ophthalmologists offer all treatments and surgical interventions relating to the eye. In this way, Vista guarantees comprehensive and lifelong care for its patients. Forward-looking research activities and the continuous training of all employees ensure quality and sustainability at all sites. A team of CMS Switzerland, led by Stefan Brunnschweiler and Franziska Hammer, advised Vista Augenpraxen & Kliniken on all legal matters of the transaction. CMS Switzer­land­Stefan Brunnschweiler, Partner, Corporate / M&AFranziska Hammer, Counsel, Corporate / M&A          Christoph Willi, Partner, Life Science & HealthcareMiryam Meile, Associate, EmploymentRafael Gruber, Attorney Trainee

Zurich, March 2024 | An international CMS team under the lead of Stefan Brunnschweiler and Florian Jung provided comprehensive advice to Ypsomed (SIX: YPSN) on all legal aspects regarding the sale of its pen needle and blood glucose monitoring systems (BGMs) businesses to Medical Technology and Devices S.p.A. (MTD). Ypsomed is supporting a reliable transition to ensure the supply of pen needles to people around the globe who inject insulin and other hormones. During a transition period, Ypsomed will produce pen needles as a contract manufacturer and provide certain services to facilitate a seamless transfer. The production equipment will be gradually moved to the MTD sites by mid-2025. The business with pen needles and BGMs to be transferred to MTD accounted for sales of CHF 52 million in FY 2022/23 and CHF 18 million in the first half of FY 2023/24. The closing of the transaction and thus the transfer of the business with pen needles and blood glucose monitoring systems is expected in summer 2024, after which the transition will begin, and is subject to customary respectively regulatory conditions. Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in busi­ness-to-busi­ness operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners. Ypsomed has over 2,200 employees worldwide. CMS ZurichStefan Brunnschweiler, LL.M., Managing Partner, Head Corporate/M&AFlorian Jung, LL.M., Senior Associate, Corporate/M&ASamuel Felix Gang, LL.M., Senior Associate, Corporate/M&AAnna Mast, Associate, Corporate/M&AAlexander Salamon, Attorney Trainee, Corporate/M&AMarquard Christen, LL.M., MAS, Partner, Com­pet­i­tion­Sophia Rovelli, Attorney Trainee, Com­pet­i­tion­Nad­ine Anwander, Attorney Trainee, CompetitionDr Matthias Kuert, LL.M., Partner, Capital MarketsMark Cagienard, LL.M. VAT, Partner, TaxChristian Gersbach, LL.M., Partner, EmploymentDirk Spacek, LL.M., Partner, IT/IPCMS ParisAlexandra Rohmert, Partner, Corporate/M&AVincent Desbenoit, Associate, Corporate/M&ACaroline Froger-Michon, Partner, Em­ploy­ment­Ca­mille Baumgarten, Associate, Em­ploy­ment­Aliénor Fevre, Counsel, CommercialManon Fleury, Associate, Com­mer­cialJean-Hugues de la Berge, Partner, TaxWilliam Hamon, Partner, TaxCMS FrankfurtDr Heike Wagner, Partner, Corporate/M&ADr Tobias Kilian, Of Counsel, Corporate/M&ADr Reiner Thieme, Associate, Corporate/M&ACMS HamburgDr Heike Wagner, Partner, Corporate/M&A

This year CMS Switzerland has been recommended by The Legal 500 in 21 categories in the European, Middle Eastern and African (EMEA) edi­tion. In addition, 6 of our lawyers are recognized individually for their expertise as "Leading Individuals" or "Next Generation Partner" in the areas of Competition, Insolvency & Corporate Recovery, Insurance, Public Law, Real Estate & Construction and TMT.

Frankfurt/Main – CMS has announced the findings of the 16th edition of the CMS European M&A Study 2024, offering an in-depth analysis of the mergers and acquisitions landscape based on transactions CMS advised on. The Study analyses a record 559 deals throughout 2023, indicating the resilience and adaptability of the European M&A market amidst challenging global conditions. The high number of completed deals is testament to CMS’s strength in the market, despite the well-documented general downturn in deal activity across the globe. The 2024 Study reveals key trends in the M&A sector, including a notable shift in deal-making strategies, a rise in ESG due diligence and strategic investments outpacing financial investments. Despite a complex macroeconomic environment, the Study identifies a robust pipeline of deals for 2024, underpinned by a gradual stabilisation in the market, with lower interest rates and lower inflation. Key Findings and Takeaways: Sustained Deal Activity: Despite geopolitical tensions and economic challenges, 2023 witnessed a resilient M&A market, with CMS advising on a record number of deals. This resilience signals a robust appetite for strategic acquisitions and a promising outlook for 2024. Pricing Structures Shift: There was a notable decrease in purchase price adjustments (PPAs) and earn-outs, suggesting a move towards more stable and predictable deal structures. This trend suggests increasing confidence in valuation accuracy and financial stability. However, the reduced use of locked box structures in smaller transactions indicates lingering uncertainty regarding pricing. ESG Still Emerging in Deal Considerations: While specific ESG due diligence has seen an uptick, rising to 47% from last year's 33%, the incorporation of ESG factors into deal structures remains modest. This area is expected to grow as regulatory and reputational pressures increase. Rise in Strategic Investments: The study observed a significant presence of strategic investors both as buyers and sellers, indicating a strategic reshaping of business portfolios in response to evolving market conditions. Risk Allocation: The standard limitation period for operational warranties, although reducing, remains between 12 to 24 months across most transactions, with liability caps below 50% of the purchase price being seen in the majority of cases, maintaining consistency with previous years.W&I Insurance Stability: The utilisation of Warranty & Indemnity insurance in European deals, particularly in the larger transactions, has stayed consistent with 2022 levels, with the UK leading in its use. Geopolitical and Economic Factors: The Study acknowledges the ongoing impact of geopolitical tensions and economic uncertainties on deal-making but also points to recovering confidence in the debt markets and potential boosts from election cycles. Louise Wallace, Global Head of the CMS Corporate/M&A Group, said: “The insights from this year's Study not only highlight the resilience of the European M&A market but also point towards interesting and evolving trends that will shape the future of deal-making. Our dedication to providing unparalleled guidance has never been more relevant.”Dr Malte Bruhns, Global Head of the CMS Corporate/M&A Group, added: “Our analysis reveals a market in transformation, adapting to global challenges while identifying new opportunities. This resilience and adaptability underline the strength of our M&A advisory services.” Conclusion: The CMS European M&A Study 2024 underscores an optimistic outlook for M&A activity in Europe in 2024, highlighting resilience amid economic challenges. Key trends indicate a shift towards seller-friendly dynamics and robust deal flow, fuelled by improved market confidence and strategic entry into new markets. Read the full CMS European M&A Study 2024 here. Press Con­tact presse@cms-hs. com

Awards & Rankings

A cross-border team from CMS has advised On Location, the Endeavor-owned leader in premium experiences, hospitality, and travel, on its strategic investment in Wiz-Team, a leading event and data management technology solution. The investment will support integration of Wiz-Team’s technology and software across the On Location portfolio, with a focus on enhancing guest registration and communication, accreditation, accommodation, and access con­trol. Already, On Location has partnered with Wiz-Team to enhance guest management services across its marquee VIP experiences, travel, and hospitality offerings, including the Olympic and Paralympic Games (for which On Location is the official, exclusive hospitality provider through to the Los Angeles 2028 Olympic and Paralympic Games), Super Bowl, and the Aer Lingus Classic. A team of CMS Zurich and London, led by partner Dr Daniel Jenny and senior associate Florian Jung (both CMS Zurich) as well as partner Nick Crosbie and senior associate Lauren Wood (both CMS London) has advised Endeavor / On Location on this trans­ac­tion.  The team further consisted of Samuel Gang (senior associate; corporate), Alexander Salamon (attorney trainee; corporate), Christian Gersbach (partner; employment), Miryam Meile (senior associate; employment), Mark Cagienard (partner; tax), Dirk Spacek (partner; IP/IT), Michelle Lindenman (associate; real estate; all CMS Zurich); Tetyana Dovgan (partner; corporate), Mariana Saienko (senior associate; corporate); Ihor Pavliukov (associate; corporate; all CMS Kyiv), Marco Casasole (partner; corporate; corporate), Francesco Capasso (Counsel; corporate), Giusy Lauro (counsel; employment; all CMS Rome), David Prync (partner; corporate), and Ségolène Regout (senior associate; corporate; both CMS Brussels). CMS ZurichDr Daniel Jenny, Partner, Corporate/M&AFlorian Jung, Senior Associate, Corporate/M&ASamuel Gang, Senior Associate, Corporate/M&AAlexander Salamon, Attorney Trainee, Corporate/M&AChristian Gersbach, Partner, EmploymentMiryam Meile, Senior Associate, EmploymentMark Cagienard, Partner, TaxDirk Spacek, Partner, IP/ITMichelle Lindenmann, Associate, Real EstateCMS LondonNick Crosbie, Partner, Corporate/M&ALauren Wood, Senior Associate, Corporate/M&ACMS KyivTetyana Dovgan, Partner, Corporate/M&AMariana Saienko, Senior Associate, Corporate/M&AIhor Pavliukov, Associate, Corporate/M&ACMS RomeMarco Casasole, Partner, Corporate/M&AFrancesco Capasso, Counsel, Corporate/M&AGiusy Lauro, Counsel, Employment CMS Brussels David Prync, Partner, Corporate/M&ASégolène Regout, Senior Associate, Corporate/M&A